667 related articles for article (PubMed ID: 23458496)
1. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II).
Blumenfeld AM; Bloudek LM; Becker WJ; Buse DC; Varon SF; Maglinte GA; Wilcox TK; Kawata AK; Lipton RB
Headache; 2013 Apr; 53(4):644-55. PubMed ID: 23458496
[TBL] [Abstract][Full Text] [Related]
2. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.
Buse D; Manack A; Serrano D; Reed M; Varon S; Turkel C; Lipton R
Headache; 2012 Jan; 52(1):3-17. PubMed ID: 22106869
[TBL] [Abstract][Full Text] [Related]
3. Similarities and differences between chronic migraine and episodic migraine.
Ferrari A; Leone S; Vergoni AV; Bertolini A; Sances G; Coccia CP; Ottani A; Pinetti D; Sternieri E
Headache; 2007 Jan; 47(1):65-72. PubMed ID: 17355496
[TBL] [Abstract][Full Text] [Related]
4. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS).
Stokes M; Becker WJ; Lipton RB; Sullivan SD; Wilcox TK; Wells L; Manack A; Proskorovsky I; Gladstone J; Buse DC; Varon SF; Goadsby PJ; Blumenfeld AM
Headache; 2011; 51(7):1058-77. PubMed ID: 21762134
[TBL] [Abstract][Full Text] [Related]
5. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
[TBL] [Abstract][Full Text] [Related]
6. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.
Bagley CL; Rendas-Baum R; Maglinte GA; Yang M; Varon SF; Lee J; Kosinski M
Headache; 2012 Mar; 52(3):409-21. PubMed ID: 21929662
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiology of chronic migraine and mode of action of preventive medications.
Mathew NT
Headache; 2011; 51 Suppl 2():84-92. PubMed ID: 21770930
[TBL] [Abstract][Full Text] [Related]
8. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
[TBL] [Abstract][Full Text] [Related]
9. Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
Serrano D; Manack AN; Reed ML; Buse DC; Varon SF; Lipton RB
Value Health; 2013; 16(1):31-8. PubMed ID: 23337213
[TBL] [Abstract][Full Text] [Related]
10. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.
Yaldo AZ; Wertz DA; Rupnow MF; Quimbo RM
Clin Ther; 2008 Dec; 30(12):2452-60. PubMed ID: 19167603
[TBL] [Abstract][Full Text] [Related]
11. Acute treatment optimization in episodic and chronic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
Serrano D; Buse DC; Manack Adams A; Reed ML; Lipton RB
Headache; 2015 Apr; 55(4):502-18. PubMed ID: 25881676
[TBL] [Abstract][Full Text] [Related]
12. Persistent frequent nausea is associated with progression to chronic migraine: AMPP study results.
Reed ML; Fanning KM; Serrano D; Buse DC; Lipton RB
Headache; 2015 Jan; 55(1):76-87. PubMed ID: 25250833
[TBL] [Abstract][Full Text] [Related]
13. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
14. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
Lipton RB; Buse DC; Serrano D; Holland S; Reed ML
Headache; 2013 Sep; 53(8):1300-11. PubMed ID: 23879870
[TBL] [Abstract][Full Text] [Related]
15. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study.
Buse DC; Manack AN; Fanning KM; Serrano D; Reed ML; Turkel CC; Lipton RB
Headache; 2012; 52(10):1456-70. PubMed ID: 22830411
[TBL] [Abstract][Full Text] [Related]
16. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme.
Ueda K; Ye W; Lombard L; Kuga A; Kim Y; Cotton S; Jackson J; Treuer T
J Headache Pain; 2019 Jun; 20(1):68. PubMed ID: 31174464
[TBL] [Abstract][Full Text] [Related]
17. [Treatment guidelines for preventive treatment of migraine].
Treatment Guideline Subcommittee of the Taiwan Headache Society
Acta Neurol Taiwan; 2008 Jun; 17(2):132-48. PubMed ID: 18686655
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
19. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
20. Asthma is a risk factor for new onset chronic migraine: Results from the American migraine prevalence and prevention study.
Martin VT; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
Headache; 2016 Jan; 56(1):118-31. PubMed ID: 26581563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
